Anthony Mato
MD, MSCE
Director, CLL Program
👥Biography 个人简介
Anthony Mato led early-phase investigation of pirtobrutinib, the first non-covalent (reversible) BTK inhibitor, in patients with MCL and CLL who had progressed on prior covalent BTK inhibitor therapy. His work on the BRUIN trial demonstrated impressive response rates in post-ibrutinib MCL patients. He is internationally recognized for expertise in BTK inhibitor sequencing and resistance mechanisms.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Anthony Mato 的研究动态
Follow Anthony Mato's research updates
留下邮箱，当我们发布与 Anthony Mato（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment